News - Appointments

Darrin Disley, until recently the chief executive of Horizon Discovery Group Plc, has been appointed an Officer of the Order of the British Empire (OBE) in recognition of his service to UK life science.

The UK-based pharmaceutical manufacturer, Hikma Pharmaceuticals Plc, has appointed Henriette Nielsen to the newly created position of chief transformation officer where she will help oversee global operations.

Cancer Research UK has appointed Tony Hickson as chief business officer to oversee the commercial development of the charity’s research, effective August.

Roger Connor, a member of GlaxoSmithKline Plc’s executive team since 2012, has been appointed president of vaccines, effective 1 September, following the decision by Luc Debruyne to leave the company at the end of the year.

Marc Dunoyer, chief financial officer at AstraZeneca Plc, is one of two new independent directors of Orchard Therapeutics Ltd, a developer of gene therapies for rare diseases.

Jonathan Appleby, currently an executive at the rare disease unit of GlaxoSmithKline Plc, will join the UK Cell and Gene Therapy Catapult on 1 October as chief scientific officer.

Mark Goldberger, a former official at the US Food and Drug Administration, has joined the advisory board of the NDA regulatory consultancy.

Sygnature Discovery Ltd has appointed Bill Marathias, a former Pfizer Inc scientist, as head of business development for the US.

Nordic Nanovector ASA has appointed Maureen Deehan as head of corporate development and strategy to work alongside its chief operating officer in overseeing the development of therapies for haematological cancers.

David Roblin, president of research and development at Summit Therapeutics Plc, has been appointed chair of a new scientific advisory board at Destiny Pharma Plc to help guide development of the company’s anti-microbial drug portfol